SG Mart Ltd
SGMARTSG Mart Ltd's price has outrun its earnings. +102.0% in a year against EPS −4.2% — the market is paying now for delivery later.
The sharpest disagreement: profits are rising, but only −37% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch.
The price is in a confirmed uptrend (32 weeks in) while the P/E sits at the 65th percentile of its own 10-year range. Underneath, the last four quarters read improving — profit +43.8% year on year, and −37% of the last 3 years' profit arrived as cash. What settles it: whether the cash starts following the profit.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
SG Mart Ltd trades at ₹734, in a confirmed uptrend and 32 weeks into that stage. That is +24.2% against its own 200-day average. It sits at 81% of a 52-week range of ₹334 to ₹826. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 12 straight weeks.
Today the stock is in a confirmed uptrend — week 32 of stage 2, confirmed. At ₹734 it trades +24.2% versus its 200-day average and sits at 81% of its 52-week range (₹334–₹826).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +59,057% while the NIFTY 500 moved +251% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 12 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
SG Mart Ltd trades at 74.1× P/E, mid-range by its own standards (65th percentile). Its long-run median P/E is 47.0×, measured across 10.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 74.1× is mid-range by its own standards (65th percentile), against a long-run median of 47.0× measured over 10.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −4.2% against a +102.0% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 5y, of the +111.2%/yr price move, ~+116.0%/yr came from earnings growth and ~−4.8 pp from the multiple (compressing); over 10y, of the +86.5%/yr price move, ~+66.6%/yr came from earnings growth and ~+19.9 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, SG Mart Ltd was paying for profit growth of about 33.2% a year. Today the market pays 74.1× P/E, the 65th percentile of its own 10-year range.
What the two numbers say together. The multiple is full against its own past, and the growth the price is paying for is the whole of what a buyer is backing.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 25 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
SG Mart Ltd reads as mixed on its fundamental arc. Mixed — eps growth is lifting off its trough at +4.7% while profit growth is decelerating from its peak at +14.7% — the curves disagree, so the per-curve reads carry the story. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +7.8% | — | — | +139.9% |
| Profit | +7.8% | — | — | — |
| EPS | −4.2% | — | — | +64.7% |
| Share price | +102.0% | +40.2% | +111.2% | +86.5% |
4-Factor Sector Score
48.3/100 — rank 24 of 58 in Trading · 93% evidence confidence
SG Mart Ltd scores 48.3 out of 100 against the 58 companies it is compared with in Trading, ranking 24. Price leads the evidence: RS versus the benchmark is 45.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 13.7 + 8.4 + 8.2 + 18 = 48.3. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
SG Mart Ltd reported ₹1,309 Cr of revenue in the Jun 26 quarter, +14.4% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 139.9% a year. The last full year, FY26, came in at ₹6,315 Cr. The last four reported quarters add to ₹6,480 Cr.
FY26 revenue came in at ₹6,315 Cr (+7.8% on the year), capping 10 years at 139.9% compound. The latest quarter (Jun 26) printed ₹1,309 Cr, +14.4% year on year — the 3rd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +11.7% growth against the decade's 139.9% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +10.4% over the last 4 quarters against +33.0%/yr over the last 8 — rolling over; TTM profit +14.7% vs +20.6%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
SG Mart Ltd's operating margin is 4.5% in the Jun 26 quarter, +1.4 percentage points against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 1.8% to 89.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 4.5%, +1.4 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 1.8%–89.0%.
Why the margin moved: operating margin went +1.4 pp year on year while gross margin went +1.9 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
SG Mart Ltd earned ₹46.0 Cr of net profit in the Jun 26 quarter, +43.8% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹111 Cr. That is 3.5% of the quarter's revenue. The same quarter a year earlier earned ₹32.0 Cr.
Jun 26 profit was ₹46.0 Cr, +43.8% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹111 Cr (+7.8%).
Why profit moved: revenue contributed +14.4% and the margin +1.4 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +19.0% vs revenue +11.7%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −37% of SG Mart Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹258 Cr of operating cash against ₹111 Cr of profit. After ₹125 Cr of capital spending, ₹133 Cr was left as free cash.
FY26: operating cash of ₹258 Cr against reported profit of ₹111 Cr, leaving free cash of ₹133 Cr after ₹125 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −37% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −37%: the cash cycle tightened 107 days between FY17 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: the bigger cash user is investment — capital spending ran 22.8× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
SG Mart Ltd's cash conversion cycle runs 10 days in FY26, down from 117 days in FY17. Capital spending ran ₹342 Cr over the last 3 years. At FY26 sales of ₹6,315 Cr each day of that cycle holds about ₹17.3 Cr, so roughly ₹173 Cr sits inside the business at any moment.
FY26: debtors at 15 days, inventory at 18 days — roughly 0.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 10 days, tighter than FY17's 117.
The full loop: cash goes out to suppliers and production on day 0; stock waits 18 days to sell; customers pay about 15 days after that; and suppliers themselves are paid at 24 days — netting out to the 10-day cycle.
In money terms: at FY26 sales of ₹6,315 Cr, each day of the cycle holds about ₹17.3 Cr — so the 10-day loop keeps roughly ₹173 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹342 Cr over the last 3 fiscal years against ₹15.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹20.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
SG Mart Ltd earns a ROCE of 10% in FY26. That is up from a trough of 8% in FY19. Return on invested capital clears the cost of that capital by −1.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 1.8% net margin on 2.81× asset turns.
FY26 ROCE is 10%, recovered from a FY19 trough of 8% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 1.8% net margin × 2.81× asset turns × 1.41× balance-sheet leverage ≈ 7.1% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 10.3% − 12.0% = a −1.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
SG Mart Ltd carries total debt of ₹268 Cr against shareholder equity of ₹1,597 Cr as of Jun 26, a debt-to-equity of 0.17 — effectively unlevered. On the annual view that ratio went from 0.17 in FY24 to 0.17 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of ₹268 Cr against shareholder equity of ₹1,597 Cr — a debt-to-equity of 0.17. On the annual view, debt-to-equity went from 0.17 (FY24) to 0.17 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 16.9 points of SG Mart Ltd over 8 quarters, the biggest move on the register. That takes promoters to 57.9% of the company. Foreign institutions moved −3.7 points over the same window, to 1.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +16.9 points over 8 quarters to 57.9%; Foreign institutions: −3.7 points over 8 quarters to 1.9%; Domestic institutions: +3.6 points over 8 quarters to 4.1%.
Why the register moved: rotation — foreign institutions −3.7 points against domestic institutions +3.6 points over 8 quarters, with promoters +16.9 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
SG Mart Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nupur Recyclers LtdNRL | 67.5/100Favorable setup87% evidence | LEADER | 22.2/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.6/25 ROCE 15.1% · OPM 11.6% 95% evidence | 8.8/20 P/E 65.1× · PEG — 50% evidence | 19.9/20 RS sector 91.7% · RS bench 122% · 1Y 108.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 16.6 + 8.8 + 19.9 = 67.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Magnus Steel & Infra Ltd517320 | 67.2/100Thin evidence · provisional56% evidence | 27.5/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 46.1% · 1Y 1238.7%11 of 12 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.5 + 18.5 + 9.2 + 12 = 67.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Vision Infra Equipment Solutions LtdVIESL | 66.5/100Thin evidence · provisional56% evidence | BREAKING OUT | 18.9/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.9/25 ROCE 22.6% · OPM 26% 95% evidence | 10.9/20 P/E 14× · PEG — 15% evidence | 16.8/20 RS sector 14.5% · RS bench 34.1% · 1Y 52.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 19.9 + 10.9 + 16.8 = 66.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Rashi Peripherals LtdRPTECH | 63.3/100Mixed-positive evidence75% evidence | LEADER | 24.3/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 17% · OPM 3% 76% evidence | 10.6/20 P/E 18.6× · PEG — 15% evidence | 13.7/20 RS sector 55.9% · RS bench 78.7% · 1Y 180.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 14.7 + 10.6 + 13.7 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shankara Buildpro LtdBUILDPRO | 62.8/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.1/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.4/25 ROCE 39% · OPM 3.2% 100% evidence | 10.3/20 P/E 23.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 25.1 + 17.4 + 10.3 + 10 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Pramara Promotions LtdPRAMARA | 61.7/100Mixed-positive evidence69% evidence | 22.3/35 Revenue 72.7% · PAT 100% · OPM change 1 pp 59% evidence | 14.3/25 ROCE 15% · OPM 14.6% 95% evidence | 14.4/20 P/E 14.2× · PEG — 50% evidence | 10.7/20 RS sector 7.9% · RS bench -60.1% · 1Y -62.9%10 of 12 weeks ahead 70% evidence | |
| Exact sum: 22.3 + 14.3 + 14.4 + 10.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Tembo Global Industries LtdTEMBO | 61.4/100Mixed-positive evidence80% evidence | TURNING | 21.7/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.5/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.6× · PEG — 15% evidence | 9.9/20 RS sector -15.7% · RS bench 0.5% · 1Y -4.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 18.5 + 11.3 + 9.9 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Arisinfra Solutions LtdARIS | 58.5/100Mixed-positive evidence65% evidence | BREAKING OUT | 21.7/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.1/25 ROCE 15.6% · OPM 11% 95% evidence | 10.6/20 P/E 17.4× · PEG — 15% evidence | 11.1/20 RS sector — · RS bench 12.5% · 1Y -12.1%6 of 11 weeks ahead 25% evidence |
| Exact sum: 21.7 + 15.1 + 10.6 + 11.1 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Ivalue Infosolutions LtdIVALUE | 58.5/100Mixed-positive evidence65% evidence | ASLEEP | 20.2/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.1× · PEG — 15% evidence | 8.5/20 RS sector — · RS bench -11.3% · 1Y -18.7%5 of 11 weeks ahead 25% evidence |
| Exact sum: 20.2 + 18.6 + 11.2 + 8.5 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Mangalam Global Enterprise LtdMGEL | 58.4/100Mixed-positive evidence80% evidence | 25.1/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.9/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 6.3/20 RS sector -15% · RS bench -0.2% · 1Y -6.2%4 of 5 weeks ahead to 2026-08-09 100% evidence | |
| Exact sum: 25.1 + 15.9 + 11.1 + 6.3 = 58.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15% and the one-year return is -6.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 11Euro Pratik Sales LtdEUROPRATIK | 57.7/100Mixed-positive evidence78% evidence | ASLEEP | 14.9/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.4/25 ROCE 36.9% · OPM 26% 100% evidence | 15.2/20 P/E 25.3× · PEG 0.62 65% evidence | 8.2/20 RS sector — · RS bench -20.6% · 1Y -9.2%5 of 11 weeks ahead 25% evidence |
| Exact sum: 14.9 + 19.4 + 15.2 + 8.2 = 57.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Singer India LtdSINGERIND | 57.3/100Thin evidence · provisional52% evidence | 26.1/35 Revenue 43.5% · PAT 100% · OPM change 6.5 pp 71% evidence | 10.2/25 ROCE 10.9% · OPM 2.5% 76% evidence | 10.1/20 P/E 25.9× · PEG — 15% evidence | 10.9/20 RS sector — · RS bench 9.7% · 1Y — 25% evidence | |
| Exact sum: 26.1 + 10.2 + 10.1 + 10.9 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.7/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.0/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.1/25 ROCE 18.9% · OPM 6% 76% evidence | 8.8/20 P/E 253× · PEG — 15% evidence | 13.8/20 RS sector -0.7% · RS bench 17.3% · 1Y 35.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 13.1 + 8.8 + 13.8 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Sudarshan Pharma Industries Ltd543828 | 56.4/100Mixed-positive evidence82% evidence | FADING | 20.5/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.7/25 ROCE 15.1% · OPM 9.1% 76% evidence | 8.5/20 P/E 38.2× · PEG — 50% evidence | 13.7/20 RS sector 11.1% · RS bench 29.7% · 1Y 32.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 13.7 + 8.5 + 13.7 = 56.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Lloyds Enterprises LtdLLOYDSENT | 55.0/100Mixed-positive evidence75% evidence | TURNING | 18.0/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.2/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 107× · PEG — 15% evidence | 16.7/20 RS sector 6.1% · RS bench 24.9% · 1Y 19.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.2 + 9.1 + 16.7 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Onix Solar Energy LtdONIXSOLAR | 54.8/100Mixed-positive evidence69% evidence | 20.6/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 11.7/25 ROCE 11.3% · OPM 30% 76% evidence | 10.1/20 P/E 27.5× · PEG — 15% evidence | 12.4/20 RS sector 68.4% · RS bench -25.8% · 1Y 19.8%12 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 11.7 + 10.1 + 12.4 = 54.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Patel Retail LtdPATELRMART | 53.2/100Mixed-positive evidence65% evidence | FADING | 17.9/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.3/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.7/20 P/E 16.6× · PEG — 15% evidence | 10.3/20 RS sector — · RS bench 2.1% · 1Y -12.3%4 of 11 weeks ahead 25% evidence |
| Exact sum: 17.9 + 14.3 + 10.7 + 10.3 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Prostarm Info Systems LtdPROSTARM | 51.8/100Mixed-positive evidence65% evidence | TURNING | 16.6/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 16.0/25 ROCE 18% · OPM 8.5% 95% evidence | 10.4/20 P/E 22.7× · PEG — 15% evidence | 8.8/20 RS sector — · RS bench -4.7% · 1Y -31.9%0 of 11 weeks ahead 25% evidence |
| Exact sum: 16.6 + 16 + 10.4 + 8.8 = 51.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Pervasive Commodities Ltd517172 | 51.0/100Thin evidence · provisional52% evidence | TURNING | 16.6/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 14.4/25 ROCE 22.1% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 2 weeks ahead 0% evidence |
| Exact sum: 16.6 + 14.4 + 10 + 10 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Fabtech Technologies LtdFABTECH | 50.9/100Thin evidence · provisional52% evidence | ASLEEP | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.4/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -25.2%0 of 11 weeks ahead 0% evidence |
| Exact sum: 17.5 + 12.4 + 11 + 10 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21BMW Ventures LtdBMW | 49.8/100Thin evidence · provisional55% evidence | 16.7/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 12.0/25 ROCE 12% · OPM 3.4% 76% evidence | 11.1/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead to 2026-08-23 0% evidence | |
| Exact sum: 16.7 + 12 + 11.1 + 10 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Yogi LtdYOGI | 48.8/100Thin evidence · provisional58% evidence | 20.1/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 10.1/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.4/20 P/E 55.5× · PEG — 15% evidence | 9.2/20 RS sector -6.5% · RS bench 2.3% · 1Y -4.3%2 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.1 + 10.1 + 9.4 + 9.2 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Bizotic Commercial Ltd543926 | 48.6/100Thin evidence · provisional58% evidence | BASING | 19.7/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.7/25 ROCE 26.8% · OPM 8% 76% evidence | 9.3/20 P/E 36.6× · PEG — 50% evidence | 0.9/20 RS sector -85.7% · RS bench -11.9% · 1Y -76.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 18.7 + 9.3 + 0.9 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24SG Mart Ltdthis pageSGMART | 48.3/100Mixed-negative evidence93% evidence | LEADER | 13.7/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.4/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 74.1× · PEG 1.92 65% evidence | 18.0/20 RS sector 25.9% · RS bench 45.7% · 1Y 91.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.7 + 8.4 + 8.2 + 18 = 48.3 · Decision use: Price leads the evidence: RS versus the benchmark is 45.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25Shiv Aum Steels LtdSHIVAUM | 47.6/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.8/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 7.3/20 P/E 73.2× · PEG — 50% evidence | 12.1/20 RS sector — · RS bench 49.9% · 1Y —8 of 8 weeks ahead 25% evidence |
| Exact sum: 16.8 + 11.4 + 7.3 + 12.1 = 47.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26State Trading Corporation of India LtdSTCINDIA | 46.7/100Thin evidence · provisional57% evidence | ASLEEP | 22.8/35 Revenue — · PAT 100% · OPM change — 57% evidence | 7.6/25 ROCE 7.6% · OPM — 80% evidence | 10.8/20 P/E 15.6× · PEG — 15% evidence | 5.5/20 RS sector -28.7% · RS bench -6.8% · 1Y -11.5%1 of 12 weeks ahead 70% evidence |
| Exact sum: 22.8 + 7.6 + 10.8 + 5.5 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Dhunseri Ventures LtdDVL | 46.6/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.5/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 39% 95% evidence | 11.9/20 P/E 5.3× · PEG — 50% evidence | 12.8/20 RS sector -6.5% · RS bench 11.7% · 1Y -19.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.5 + 9.4 + 11.9 + 12.8 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28MMTC LtdMMTC | 42.3/100Mixed-negative evidence96% evidence | ASLEEP | 15.0/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 7.8/25 ROCE 8.7% · OPM — 84% evidence | 15.6/20 P/E 43.5× · PEG 0.92 100% evidence | 3.9/20 RS sector -21% · RS bench -6.1% · 1Y -13.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 7.8 + 15.6 + 3.9 = 42.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 29Hexa Tradex LtdHEXATRADEX | 41.7/100Mixed-negative evidence65% evidence | TURNING | 17.0/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.2/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.5/20 RS sector -17.1% · RS bench -1.3% · 1Y -11.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.2 + 10 + 8.5 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Cropster Agro Ltd523105 | 41.1/100Mixed-negative evidence69% evidence | ASLEEP | 15.3/35 Revenue 28.4% · PAT 6.5% · OPM change 1.7 pp 95% evidence | 11.7/25 ROCE 12.4% · OPM 9.8% 76% evidence | 10.8/20 P/E 15.6× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -73.3% · 1Y -86.8%0 of 4 weeks ahead 70% evidence |
| Exact sum: 15.3 + 11.7 + 10.8 + 3.3 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Adani Enterprises LtdADANIENT | 41.0/100Mixed-negative evidence93% evidence | ASLEEP | 14.1/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.3/25 ROCE 5.8% · OPM 15% 100% evidence | 7.6/20 P/E 166× · PEG 1.96 65% evidence | 11.0/20 RS sector 1% · RS bench 18.4% · 1Y 19.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 8.3 + 7.6 + 11 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32RRP Semiconductor LtdRRP | 40.9/100Thin evidence · provisional54% evidence | 11.2/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.6/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.1/20 RS sector 65.3% · RS bench 0.8% · 1Y 36.6%0 of 1 week ahead to 2026-08-23 70% evidence | |
| Exact sum: 11.2 + 5.6 + 10 + 14.1 = 40.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Le Merite Exports LtdLEMERITE | 40.1/100Thin evidence · provisional57% evidence | 18.0/35 Revenue — · PAT — · OPM change -15.5 pp 45% evidence | 6.8/25 ROCE 9.9% · OPM -10.7% 95% evidence | 9.1/20 P/E 94.5× · PEG — 15% evidence | 6.2/20 RS sector -9% · RS bench -68.5% · 1Y -94.7%0 of 2 weeks ahead 70% evidence | |
| Exact sum: 18 + 6.8 + 9.1 + 6.2 = 40.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Blue Pearl Agriventures LtdBPAGRI | 39.2/100Mixed-negative evidence69% evidence | 20.0/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.2/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -88.6%1 of 12 weeks ahead to 2026-08-23 70% evidence | |
| Exact sum: 20 + 6.2 + 8.7 + 4.3 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Riddhi Siddhi Gluco Biols Ltd524480 | 39.0/100Mixed-negative evidence82% evidence | FADING | 12.4/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.5/25 ROCE 2.7% · OPM -3% 76% evidence | 6.3/20 P/E 37.4× · PEG — 50% evidence | 13.8/20 RS sector 7.8% · RS bench 25.9% · 1Y 28.1%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 6.5 + 6.3 + 13.8 = 39 · Decision use: Price leads the evidence: RS versus the benchmark is 25.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 36Hardwyn India LtdHARDWYN | 38.7/100Mixed-negative evidence87% evidence | ASLEEP | 13.5/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.3/25 ROCE 4.8% · OPM 13% 95% evidence | 11.1/20 P/E 51.2× · PEG — 50% evidence | 1.8/20 RS sector -38.8% · RS bench -27.7% · 1Y -3.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 12.3 + 11.1 + 1.8 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Neueon Corporation LtdNEUEON | 37.6/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.9/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.6/20 RS sector 12.7% · RS bench 16.3% · 1Y —0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.9 + 10 + 14.6 = 37.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38PTC India LtdPTC | 36.6/100Mixed-negative evidence82% evidence | BASING | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.7/25 ROCE 13.4% · OPM 3.1% 76% evidence | 8.9/20 P/E 9× · PEG — 50% evidence | 3.8/20 RS sector -21.7% · RS bench -7.2% · 1Y -11.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.7 + 8.9 + 3.8 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Kothari Industrial Corporation LtdKOTIC | 34.3/100Adverse evidence63% evidence | BASING | 18.7/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.7/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.9/20 RS sector -58.6% · RS bench -33.2% · 1Y -71.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 18.7 + 1.7 + 10 + 3.9 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40BN Agrochem LtdBNAGROCHEM | 32.1/100Adverse evidence77% evidence | BASING | 12.8/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.2/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 119× · PEG — 15% evidence | 6.1/20 RS sector -16.7% · RS bench -26.3% · 1Y -40.5%4 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 4.2 + 9 + 6.1 = 32.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Shanti Overseas (India) LtdSHANTI | 32.0/100Thin evidence · provisional56% evidence | 11.3/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.7/25 ROCE -25.2% · OPM -216.5% 71% evidence | 12.4/20 P/E 3× · PEG — 50% evidence | 3.6/20 RS sector -60.4% · RS bench -49.7% · 1Y -45.6%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.3 + 4.7 + 12.4 + 3.6 = 32 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Uniphos Enterprises LtdUNIENTER | 29.8/100Adverse evidence69% evidence | ASLEEP | 12.3/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.5/25 ROCE 0.8% · OPM — 80% evidence | 8.3/20 P/E 30.9× · PEG — 50% evidence | 4.7/20 RS sector -43.6% · RS bench -20.6% · 1Y -42.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 12.3 + 4.5 + 8.3 + 4.7 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 43Oswal Agro Mills LtdOSWALAGRO | 24.7/100Adverse evidence67% evidence | BASING | 2.9/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.7/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -50.3% · RS bench -30.3% · 1Y -55.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 2.9 + 7.7 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Susan Electricals India Ltd544793 | 58.9/100Thin evidence · provisional31% evidence | 20.6/35 Revenue — · PAT — · OPM change 7.8 pp 26% evidence | 18.1/25 ROCE 37% · OPM 11.9% 76% evidence | 10.2/20 P/E 23.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 20.6 + 18.1 + 10.2 + 10 = 58.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Q-Line Biotech LtdQLINE | 57.7/100Thin evidence · provisional31% evidence | TURNING | 17.9/35 Revenue — · PAT — · OPM change 10 pp 13% evidence | 19.8/25 ROCE 22.5% · OPM 31% 95% evidence | 10.0/20 P/E 27.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 17.9 + 19.8 + 10 + 10 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46DC Infotech & Communication LtdDCI | 57.5/100Thin evidence · provisional35% evidence | TURNING | 18.4/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.7/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.4/20 P/E 22.7× · PEG — 15% evidence | 11.0/20 RS sector — · RS bench 10.5% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 18.4 + 17.7 + 10.4 + 11 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Mardia Samyoung Capillary Tubes Company LtdMSCTC | 57.0/100Thin evidence · provisional32% evidence | 20.9/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.3/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 74.6% · 1Y 59.1%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.9 + 15.3 + 8.6 + 12.2 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Proventus Agrocom LtdPROV | 56.5/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.5/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.7/25 ROCE 11.5% · OPM 1.8% 95% evidence | 12.5/20 P/E 47.8× · PEG — 50% evidence | 11.8/20 RS sector — · RS bench 39.7% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.5 + 12.7 + 12.5 + 11.8 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49SK Minerals & Additives Ltd544584 | 55.5/100Thin evidence · provisional36% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.1/25 ROCE 26.2% · OPM 10.7% 76% evidence | 9.9/20 P/E 29.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 6 weeks ahead 0% evidence |
| Exact sum: 16.5 + 19.1 + 9.9 + 10 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Arvaya Healthcare LtdARVAYA | 54.7/100Thin evidence · provisional19% evidence | 18.6/35 Revenue — · PAT — · OPM change 46.1 pp 10% evidence | 12.3/25 ROCE — · OPM 13% 30% evidence | 11.4/20 P/E 3.9× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 104.2% · 1Y — 25% evidence | |
| Exact sum: 18.6 + 12.3 + 11.4 + 12.4 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Monika Alcobev LtdMONIKA | 53.9/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.5/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -19.3%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.5 + 10 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52Shah Foods Ltd519031 | 53.5/100Thin evidence · provisional18% evidence | BREAKING OUT | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.9/20 P/E 246× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 75.6% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.9 + 12.2 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 53Manbro Industries Ltd512595 | 51.0/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.2/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 75.3%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.2 + 10 + 9.5 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 54Satani Bearings Ltd505703 | 45.2/100Thin evidence · provisional38% evidence | TURNING | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.7/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5287× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 24.6% · 1Y 181.4%3 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.7 + 8.6 + 11.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Keto Motors Ltd537392 | 43.2/100Thin evidence · provisional38% evidence | BREAKING OUT | 16.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 7722× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 241.5% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 16.2 + 6 + 8.5 + 12.5 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 56A-1 LtdA1L | 41.0/100Thin evidence · provisional50% evidence | 16.1/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.7/20 P/E 383× · PEG — 15% evidence | 5.5/20 RS sector -24.5% · RS bench -16% · 1Y -10.6%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.1 + 10.7 + 8.7 + 5.5 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Aerpace Industries Ltd534733 | 40.5/100Thin evidence · provisional32% evidence | 13.0/35 Revenue — · PAT -80% · OPM change — 33% evidence | 5.6/25 ROCE -21.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.9/20 RS sector — · RS bench 44% · 1Y — 25% evidence | |
| Exact sum: 13 + 5.6 + 10 + 11.9 = 40.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Prabhatam Infra Venture LtdPRABHATAM | 39.2/100Thin evidence · provisional22% evidence | 16.1/35 Revenue — · PAT -80% · OPM change — 8% evidence | 3.1/25 ROCE -97.1% · OPM -23.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.1 + 3.1 + 10 + 10 = 39.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is SG Mart Ltd's share price today?
SG Mart Ltd trades at ₹734, +102.0% over the past year. The company is valued at ₹9,216 Cr. The stock sits at 81% of its 52-week range of ₹334–₹826, +24.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 32 weeks in. — as of 25 September 2026.
What were SG Mart Ltd's latest quarterly results?
SG Mart Ltd reported revenue of ₹1,309 Cr and net profit of ₹46.0 Cr for the Jun 26 quarter. Revenue rose 14.4% and profit rose 43.8% year on year. Earnings per share were ₹3.62. The operating margin was 4.5%, 1.4 pp higher than a year earlier. — as of 25 September 2026.
What is SG Mart Ltd's revenue?
SG Mart Ltd reported revenue of ₹1,309 Cr in the Jun 26 quarter, +14.4% year on year. For the full FY26 fiscal year, revenue was ₹6,315 Cr (+7.8%). Over the last 10 years revenue compounded at 139.9% a year. — as of 25 September 2026.
What is SG Mart Ltd's profit?
SG Mart Ltd earned ₹46.0 Cr of net profit in the Jun 26 quarter, +43.8% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹111 Cr. The operating margin ran 4.5% in the latest quarter. — as of 25 September 2026.
What is SG Mart Ltd's market cap?
SG Mart Ltd's market capitalisation is ₹9,216 Cr at a share price of ₹734. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 25 September 2026.
What is SG Mart Ltd's P/E ratio?
SG Mart Ltd trades at a P/E of 74.1×, at the 65th percentile of its own 10-year range, against a long-run median of 47.0×. This is a comparison with the stock's own history, not a value call — as of 25 September 2026.
Does SG Mart Ltd pay a dividend?
Not in its latest year — SG Mart Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 4 of its last 7 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 25 September 2026.
Is SG Mart Ltd overvalued?
On its own history, SG Mart Ltd looks expensive: its P/E of 74.1× sits at the 65th percentile of its 10-year range (long-run median 47.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 25 September 2026.
Is SG Mart Ltd growing?
Yes — SG Mart Ltd is growing: latest-quarter revenue +14.4% year on year, profit +43.8%, and the margin +1.4 pp at 4.5%. The earnings engine currently reads: improving — as of 25 September 2026.
How is SG Mart Ltd performing?
SG Mart Ltd is in a confirmed uptrend, 32 weeks in. Its latest quarter's revenue rose 14.4% and profit rose 43.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 12 weeks. This describes what the data did, not a rating. — as of 25 September 2026.
What stage is SG Mart Ltd in?
Mixed — eps growth is lifting off its trough at +4.7% while profit growth is decelerating from its peak at +14.7% — the curves disagree, so the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +10.4% latest, profit growth +14.7% latest, eps growth +4.7% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 25 September 2026.
Is SG Mart Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 32 of stage 2), trading +24.2% versus its 200-day average and at 81% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 25 September 2026.
Is SG Mart Ltd beating the market?
On recent form, yes — SG Mart Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 12 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +59,057% against the NIFTY 500's +251% — ahead of the index over the full window. — as of 25 September 2026.
Will SG Mart Ltd's share price go up?
This page publishes no price forecast for SG Mart Ltd. What it measures instead: the share price is ₹734, the price is in a confirmed uptrend 32 weeks in. Its P/E of 74.1× sits at the 65th percentile of its own 10-year range. — as of 25 September 2026.
Who owns SG Mart Ltd?
Promoters hold 57.9% of SG Mart Ltd, foreign institutions 1.9%, domestic institutions 4.1% and the public 36.1% (latest quarter). The biggest move on the register over the last two years: Promoters added 16.9 points over 8 quarters. — as of 25 September 2026.
Does SG Mart Ltd have too much debt?
No — SG Mart Ltd's debt-to-equity is 0.17, and operating profit covers the interest bill 3×. FY26 borrowings were ₹268 Cr against equity of ₹1,597 Cr. The returns on this page are earned, not borrowed — as of 25 September 2026.
What is SG Mart Ltd's capex?
SG Mart Ltd spent ₹342 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹125 Cr, with ₹20.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 25 September 2026.
What is SG Mart Ltd's cash flow?
SG Mart Ltd generated ₹258 Cr of operating cash flow in FY26 and ₹133 Cr of free cash flow after ₹125 Cr of capital spending. Reported profit that year was ₹111 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 25 September 2026.
Is SG Mart Ltd's profit real cash?
No — operating cash was negative over the last 3 fiscal years: SG Mart Ltd consumed cash while reporting profit. In FY26, operating cash was ₹258 Cr against reported profit of ₹111 Cr. Cash-flow resolution is annual — as of 25 September 2026.
Where is SG Mart Ltd in its business cycle?
SG Mart Ltd's FY26 operating margin was 2.2%, against a 7-year band of 1.8%–89.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 4.5%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 25 September 2026.
What growth does SG Mart Ltd's price assume?
At its price on 13 June 2026, SG Mart Ltd was priced for profit growth of about 33.2% a year. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 25 September 2026.
What could break the SG Mart Ltd story?
The sharpest disagreement: profits are rising, but only −37% of the last 3 years' profit arrived as operating cash — the gap between the P&L and the bank account is the thing to watch. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 25 September 2026.
Is SG Mart Ltd a stock worth studying right now?
This is not investment advice. The machine read: SG Mart Ltd's price has outrun its earnings. +102.0% in a year against EPS −4.2% — the market is paying now for delivery later. The sharpest open question: whether the cash starts following the profit. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 25 September 2026.
Not SEBI Registered !! Not Investment advice !!